Little Pharma


Book Description

The title Little Pharma is both a doppelgänger and a cri de coeur: as the poet’s dreamlike double, the character Little Pharma navigates the murky channels of the hospital and clinic, the borderlands of the living and the dead, and the journey from novice to healer. At the same time, the poems plead for a return to a littler pharma, a space for stolen intimacy and momentary quiet amid the impersonal and engulfing chill that floods the anatomical theater and the corridors of illness. Little Pharma is a Dantean journey from the depths of an institution, and of a pervading personal dread, to a renewed celebration of human contact, the body, and the giddy, terrifying excitement of ongoing life. Excerpt from “Intensive Care” Doctor, I don my day-face like a net of cathodes, drained of all irruption, non-particular. Whose mask and sign is Sun. Enter this sickroom bugged with surging pentecosts of light, the green tracings of the representative heart. Permit now its miraculous whim.




Little Pharma


Book Description

Winner of the 2020 Agnes Lynch Starrett Prize for Poetry




Pharma


Book Description

Award-winning journalist and New York Times bestselling author Gerald Posner reveals the heroes and villains of the trillion-dollar-a-year pharmaceutical industry and delivers “a withering and encyclopedic indictment of a drug industry that often seems to prioritize profits over patients (The New York Times Book Review). Pharmaceutical breakthroughs such as anti­biotics and vaccines rank among some of the greatest advancements in human history. Yet exorbitant prices for life-saving drugs, safety recalls affecting tens of millions of Americans, and soaring rates of addiction and overdose on pre­scription opioids have caused many to lose faith in drug companies. Now, Americans are demanding a national reckoning with a monolithic industry. “Gerald’s dogged reporting, sets Pharma apart from all books on this subject” (The Washington Standard) as we are introduced to brilliant scientists, incorruptible government regulators, and brave whistleblowers facing off against company exec­utives often blinded by greed. A business that profits from treating ills can create far deadlier problems than it cures. Addictive products are part of the industry’s DNA, from the days when corner drugstores sold morphine, heroin, and cocaine, to the past two decades of dangerously overprescribed opioids. Pharma also uncovers the real story of the Sacklers, the family that became one of America’s wealthiest from the success of OxyContin, their blockbuster narcotic painkiller at the center of the opioid crisis. Relying on thousands of pages of government and corporate archives, dozens of hours of interviews with insiders, and previously classified FBI files, Posner exposes the secrets of the Sacklers’ rise to power—revelations that have long been buried under a byzantine web of interlocking companies with ever-changing names and hidden owners. The unexpected twists and turns of the Sackler family saga are told against the startling chronicle of a powerful industry that sits at the intersection of public health and profits. “Explosively, even addictively, readable” (Booklist, starred review), Pharma reveals how and why American drug com­panies have put earnings ahead of patients.




Bad Pharma


Book Description

Originally published in 2012, revised edition published in 2013, by Fourth Estate, Great Britain; Published in the United States in 2012, revised edition also, by Faber and Faber, Inc.




Rebel Cell


Book Description

Why do we get cancer? Is it our modern diets and unhealthy habits? Chemicals in the environment? An unwelcome genetic inheritance? Or is it just bad luck? The answer is all of these and none of them. We get cancer because we can't avoid it—it's a bug in the system of life itself. Cancer exists in nearly every animal and has afflicted humans as long as our species has walked the earth. In Rebel Cell: Cancer, Evolution, and the New Science of Life's Oldest Betrayal, Kat Arney reveals the secrets of our most formidable medical enemy, most notably the fact that it isn't so much a foreign invader as a double agent: cancer is hardwired into the fundamental processes of life. New evidence shows that this disease is the result of the same evolutionary changes that allowed us to thrive. Evolution helped us outsmart our environment, and it helps cancer outsmart its environment as well—alas, that environment is us. Explaining why "everything we know about cancer is wrong," Arney, a geneticist and award-winning science writer, guides readers with her trademark wit and clarity through the latest research into the cellular mavericks that rebel against the rigid biological "society" of the body and make a leap towards anarchy. We need to be a lot smarter to defeat such a wily foe—smarter even than Darwin himself. In this new world, where we know that every cancer is unique and can evolve its way out of trouble, the old models of treatment have reached their limits. But we are starting to decipher cancer's secret evolutionary playbook, mapping the landscapes in which these rogue cells survive, thrive, or die, and using this knowledge to predict and confound cancer's next move. Rebel Cell is a story about life and death, hope and hubris, nature and nurture. It's about a new way of thinking about what this disease really is and the role it plays in human life. Above all, it's a story about where cancer came from, where it's going, and how we can stop it.




Big Pharma's Sexy Little Secret


Book Description

Memoir of a pharmaceutical sales representative. An insider's expose of the extraordinarily corrupt pharmaceutical business. A series of honest, funny and disturbing short vignettes. The companies go to extremes having their attractive young reps do whatever it takes to convince doctors to push their prescription drugs and vaccines.




From Pharma to Device Sales


Book Description

From Pharma to Device Sales is a concise, straight to the point pocket guide, enabling pharmaceutical sales people to move into the medical device sales arena. There is no other book available that explores how to successfully change industries. This guide has valuable insights from recent personal experiences, up-to-date material and useful statistics – to ensure a successful industry transition. Making the switch from pharmaceutical sales to medical devices can be an uphill struggle. Are you in pharmaceutical sales looking to cross over? Have you ever wondered what selling medical devices is really like? Do you know the vital differences between selling drugs and devices? Do you want to know the typical mistakes pharmaceutical sales people make at interviews and learn how to avoid such pitfalls? This book will provide all these answers and much more! From Pharma to Device Sales is a unique, concise and inspirational book. Whatever stage you are at in your pharma career, this is a must read.




Deadly Medicines and Organised Crime


Book Description

PRESCRIPTION DRUGS ARE THE THIRD LEADING CAUSE OF DEATH AFTER HEART DISEASE AND CANCER. In his latest ground-breaking book, Peter C Gotzsche exposes the pharmaceutical industries and their charade of fraudulent behaviour, both in research and marketing where the morally repugnant disregard for human lives is the norm. He convincingly draws close co




From Breakthrough to Blockbuster


Book Description

"Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. How could a large collection of small companies, most with fewer than 50 employees, compete in one of the world's most breathtakingly expensive and highly regulated industries? This book shows how biotech companies have met the challenge by creating nearly 40% more of the most important treatments for unmet medical needs. Moreover, they have done so with much lower overall costs. The book focuses on both the companies themselves and the broader biotech ecosystem that supports them. Its portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies shows how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions. Looking to the future, it concludes that biomedical research will continue to be most effective in the hands of a large group of small companies as long as national healthcare policies allow the rest of the ecosystem to continue to thrive"--




Resilient City


Book Description

The strike against the World Trade Center on September 11, 2001, was a violent blow against the United States and a symbolic attack on capitalism and commerce. It shut down one of the world's busiest commercial centers for weeks, destroyed or damaged billions of dollars worth of property, and forced many New York City employers to slash their payrolls or move jobs to other areas. The immediate economic effect was substantial, but how badly did 9/11 affect New York City's economy in the longer term? In Resilient City, Howard Chernick and a team of economic experts examine the city's economic recovery in the three years following the destruction of the Twin Towers. Assessing multiple facets of the New York City economy in the years after 9/11, Resilient City discerns many hopeful signs among persistent troubles. Analysis by economist Sanders Korenman indicates that the value of New York–based companies did not fall relative to other firms, indicating that investors still believe that there are business advantages to operating in New York despite higher rates of terrorism insurance and concerns about future attacks. Cordelia Reimers separates the economic effect of 9/11 from the effects of the 2001 recession by comparing employment and wage trends for disadvantaged workers in New York with those in five major U.S. cities. She finds that New Yorkers fared at least as well as people in other cities, suggesting that the decline in earnings and employment for low-income New York workers in 2002 was due more to the recession than to the effects of 9/11. Still, troubles remain for New York City. Howard Chernick considers the substantial fiscal implications of the terrorist attacks on New York City, estimating that the attack cost the city about $3 billion in the first two years alone; a sum that the city now must make up through large tax increases, spending cuts, and substantial additional borrowing, which will inevitably be a burden on future budgets. The terrorist attacks of September 11 dealt a severe blow to the economy of New York City, but it was far from a knock-out punch. Resilient City shows that New York's dynamic, flexible economy has absorbed the hardships inflicted by the attacks, and provides a thorough, authoritative A Russell Sage Foundation September 11 Initiative Volume